Faculty Opinions recommendation of Risk factors for West Nile virus neuroinvasive disease, California, 2005.

Author(s):  
Edward Hayes
2007 ◽  
Vol 13 (12) ◽  
pp. 1918-1920 ◽  
Author(s):  
Cynthia M. Jean ◽  
Somayeh Honarmand ◽  
Janice K. Louie ◽  
Carol A. Glaser

2005 ◽  
Vol 161 (Supplement_1) ◽  
pp. S113-S113
Author(s):  
L B Davis ◽  
E Hayes ◽  
D O’Leary ◽  
T Smith ◽  
A Marfin ◽  
...  

2019 ◽  
Vol 10 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Andrew Yu ◽  
Emily Ferenczi ◽  
Kareem Moussa ◽  
Dean Eliott ◽  
Marcelo Matiello

West Nile virus (WNV) is the most common arbovirus infection in the United States. The diagnosis requires consideration of not only a broad spectrum of presenting symptoms, ranging from a mild febrile illness to severe encephalitis and acute flaccid paralysis, but also public health risk factors and seasonality. There is no approved targeted therapy for WNV, so treatment relies on supportive care, management of neurologic sequelae and airway, treatment of other systems including the eye, and aggressive rehabilitation. Here, we describe a series of 3 cases of WNV encountered in September 2018 at one institution. First, we describe a case of WNV encephalitis with worsened dyskinesias and a relatively good recovery. Second, we describe a severe WNV encephalitis with overlying motor neuron involvement with a poor outcome. Finally, we describe a case of a WNV meningitis with significant bilateral chorioretinitis, an underappreciated complication of WNV infections. Through these cases, we review the epidemiology of WNV, risk factors for infection, the neurologic sequalae and long-term outcomes, and the importance of recognizing ocular involvement to prevent ophthalmologic complications.


2018 ◽  
Vol 8 (2) ◽  
Author(s):  
Alyx B Porter ◽  
Akanksha Sharma ◽  
Marie F Grill ◽  
Scott Spritzer ◽  
A Arturo Leis ◽  
...  

Pathogens ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 1073
Author(s):  
Juan-Carlos Saiz

West Nile virus (WNV) is a widely distributed enveloped flavivirus transmitted by mosquitoes, which main hosts are birds. The virus sporadically infects equids and humans with serious economic and health consequences, as infected individuals can develop a severe neuroinvasive disease that can even lead to death. Nowadays, no WNV-specific therapy is available and vaccines are only licensed for use in horses but not for humans. While several methodologies for WNV vaccine development have been successfully applied and have contributed to significantly reducing its incidence in horses in the US, none have progressed to phase III clinical trials in humans. This review addresses the status of WNV vaccines for horses, birds, and humans, summarizing and discussing the challenges they face for their clinical advance and their introduction to the market.


2019 ◽  
Vol 92 ◽  
pp. 16-25
Author(s):  
Rachelle Herring ◽  
Nilesh Desai ◽  
Mered Parnes ◽  
Imad Jarjour

Sign in / Sign up

Export Citation Format

Share Document